Hot Features
프리미엄
CG Oncology Inc (CGON)
NASDAQ
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live ... CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. 더 보기
IRVINE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
- Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting...
– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024 – – Encouraging data adds to the body of evidence...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.0125 | -5.67181004721 | 35.4825 | 35.4825 | 31.28 | 598517 | 32.65137851 | CS |
| 4 | -3.21 | -8.75136314068 | 36.68 | 40.47 | 31.28 | 432095 | 35.59933334 | CS |
| 12 | -3.34 | -9.07362129856 | 36.81 | 40.47 | 31.28 | 663291 | 36.98631044 | CS |
| 26 | 4.41 | 15.1754989677 | 29.06 | 40.47 | 28.58 | 626754 | 35.25861182 | CS |
| 52 | 4.47 | 15.4137931034 | 29 | 50.23 | 25.77 | 657168 | 36.20331704 | CS |
| 156 | 4.47 | 15.4137931034 | 29 | 50.23 | 25.77 | 657168 | 36.20331704 | CS |
| 260 | 4.47 | 15.4137931034 | 29 | 50.23 | 25.77 | 657168 | 36.20331704 | CS |
